Immix Biopharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $16.3M | $11.3M | $8.7M | $4.2M | $126,527 |
| Operating expenses | $30.0M | $22.7M | $16.1M | $8.2M | $1.4M |
| Operating income | -$30.0M | -$22.7M | -$16.1M | -$8.2M | -$1.4M |
| Interest expense | — | — | — | $497 | $179,853 |
| Pretax income | -$29.4M | -$21.7M | -$15.6M | -$8.2M | -$24.4M |
| Income tax expense | $37,724 | $41,037 | $26,415 | $10,268 | $6,013 |
| Net income | -$29.4M | -$21.6M | -$15.4M | -$8.2M | -$24.4M |
| Balance Sheet | |||||
| Cash and equivalents | $93.9M | $17.7M | $17.5M | $13.4M | $17.6M |
| Current assets | $101.2M | $20.2M | $19.8M | $14.9M | $18.2M |
| Total assets | $104.8M | $22.9M | $19.9M | $14.9M | $18.2M |
| Current liabilities | $10.1M | $8.7M | $3.7M | $1.3M | $202,039 |
| Total liabilities | $11.0M | $9.7M | $3.7M | $1.7M | $202,039 |
| Stockholders' equity | $93.8M | $13.3M | $16.4M | $13.2M | $18.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$23.9M | -$14.6M | -$11.4M | -$7.4M | -$1.6M |
| Depreciation and amortization | $245,747 | $32,941 | $5,468 | $2,135 | $2,468 |
| Stock-based compensation | $2.4M | $3.0M | $2.6M | $624,069 | $218,983 |
| Capital expenditure | $732,925 | $1.2M | $52,089 | — | $802 |
| Free cash flow | -$24.7M | -$15.8M | -$11.4M | — | -$1.6M |
| Share repurchases | — | — | — | $99,963 | — |
Shares outstanding 54.4M · Free float 78.8%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.